Cargando…
Very long-term survival of an older glioblastoma patient after treatment with cilengitide: a case report
Glioblastoma (GBM) is the most common malignant brain tumor. Less than 1% of patients survive longer than 10 years. A 77-year-old woman was diagnosed with MGMT-methylated GBM in 2009. The patient received cilengitide as part of the CENTRIC clinical trial in conjunction with standard radiation and ch...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Future Medicine Ltd
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171035/ https://www.ncbi.nlm.nih.gov/pubmed/37092563 http://dx.doi.org/10.2217/cns-2022-0017 |